Exelixis, Inc. (NASDAQ:EXEL)
CAPS Rating:
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
Recs
This stock has a lot of momentum with the great performance of its prostate cancer drug, it will continue to gain speed with each new successful trial.